BMS-564929

• CAS: 627530-84-1
• Catalog Number: ALC-FP-627530841
• Category: Featured Products
• Molecular Weight: 305.72
• Molecular Formula: C14H12ClN3O3
• Appearance: White to off-white Solid
• Sample Lot No.: A23M0805x8183

Case Study

BMS-564929 for Ex Vivo Manipulation of Androgen Signaling in Mouse Fetal Reproductive Tract Culture

Jia S, et al. Differentiation, 2022, 123, 42-49.

BMS-564929 was applied as a selective androgen receptor (AR) agonist in an ex vivo organ culture system designed to model mouse fetal reproductive tract development. Entire bicornuate reproductive tracts were microdissected from embryonic mice and cultured on Transwell membrane inserts under defined orientation to preserve anatomical integrity. BMS-564929 was added directly to the culture medium to selectively activate AR signaling in genetically female (XX) tissues. Morphological outcomes were assessed by microscopic analysis of Wolffian duct maintenance and coiling. Compared with controls, BMS-564929 treatment induced ectopic stabilization of Wolffian ducts, demonstrating functional androgen responsiveness. This experimental setup highlights BMS-564929 as a powerful chemical tool for precise androgen modulation in complex organotypic cultures where in vivo manipulation is technically challenging.

BMS-564929 for UHPLC-MS/MS Screening of Selective Androgen Receptor Modulators in Urine

Ventura E, et al. Journal of Chromatography A, 2019, 1600, 183-196.

BMS-564929 served as a target analyte in the development of a semi-quantitative UHPLC-MS/MS method for multi-species screening of selective androgen receptor modulators. Urine samples (200 μL) were extracted using tert-butyl methyl ether without further cleanup, enabling rapid sample preparation. Chromatographic separation was achieved on a Polar C18 column using a 12-minute gradient with acidified water and methanol. Detection employed electrospray ionization in both positive and negative modes with selected reaction monitoring. Method validation followed EU 2002/657/EC guidelines, yielding a CCβ of 5 ng/mL for BMS-564929. This study demonstrates the compound's role as a reference standard in robust analytical workflows supporting anti-doping and residue surveillance.

BMS-564929 for Pharmacological and Structural Characterization of Androgen Receptor Selectivity

Ostrowski J, et al. Endocrinology, 2007, 148(1), 4-12.

BMS-564929 was evaluated through integrated pharmacological assays and X-ray crystallography to elucidate its tissue-selective androgenic activity. In vitro, AR agonism was quantified using receptor-binding and transactivation assays, confirming subnanomolar potency and high receptor specificity. In vivo dose-response studies were conducted in castrated male rats, measuring levator ani muscle hypertrophy and prostate growth as functional endpoints. For structural analysis, BMS-564929-AR ligand-binding domain complexes were crystallized and resolved by X-ray diffraction to identify unique ligand-receptor interactions. These experiments established a direct link between binding-mode geometry and selective co-regulator recruitment, positioning BMS-564929 as a benchmark compound for mechanistic studies of nonsteroidal AR modulators.